Warning: Creating default object from empty value in /var/www/wp-content/themes/ronneby/redux_framework/ReduxCore/inc/class.redux_filesystem.php on line 29
Evolution Bioscience https://evolution-bio.com Biotechnology Consultancy Services Tue, 05 Feb 2019 17:36:21 +0000 en-GB hourly 1 https://wordpress.org/?v=6.4.3 Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment https://evolution-bio.com/news-analysis/cell-gene-therapy-increasing-demand-for-viral-vectors-drives-biomanufacturing-innovation-cdmo-investment/ Tue, 05 Feb 2019 17:11:53 +0000 https://evolution-bio.com/?p=16011 2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record https://evolution-bio.com/news-analysis/2018-global-drug-development-ipo-review-10-24b-raised-in-strongest-year-on-record/ Tue, 15 Jan 2019 10:01:10 +0000 https://evolution-bio.com/?p=16003 RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval https://evolution-bio.com/news-analysis/rnai-therapeutics-come-of-age-exploring-the-peaks-troughs-of-alnylams-thirty-year-journey-to-first-approval/ Wed, 24 Oct 2018 16:40:18 +0000 https://evolution-bio.com/?p=15969 Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong https://evolution-bio.com/news-analysis/global-drug-development-ipos-26-companies-raise-over-3-18b-in-q3-as-first-pre-revenue-biotechs-list-in-hong-kong/ Wed, 10 Oct 2018 15:37:18 +0000 https://evolution-bio.com/?p=15959 Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution? https://evolution-bio.com/news-analysis/democratising-dna-23andme-can-blockchain-offer-a-disruptive-solution/ Mon, 13 Aug 2018 15:47:20 +0000 https://evolution-bio.com/?p=15942 Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015 https://evolution-bio.com/news-analysis/global-drug-development-ipos-over-2-5b-raised-in-q2-with-market-on-track-for-best-year-since-2015/ Fri, 13 Jul 2018 10:16:09 +0000 https://evolution-bio.com/?p=15934 Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas https://evolution-bio.com/news-analysis/lonza-opens-the-worlds-largest-cell-gene-therapy-manufacturing-plant-in-texas/ Thu, 12 Apr 2018 15:55:43 +0000 https://evolution-bio.com/?p=15906 All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation https://evolution-bio.com/news-analysis/all-eyes-on-oxford-nanopore-after-further-100m-funding-raised-at-1-5b-valuation/ Wed, 28 Mar 2018 14:52:59 +0000 https://evolution-bio.com/?p=15899 Charles River Laboratories M&A Activity Analysis: A Differentiated Strategy Delivering Results https://evolution-bio.com/news-analysis/charles-river-laboratories-ma-activity-analysis-a-differentiated-strategy-delivering-results/ Mon, 12 Mar 2018 16:46:24 +0000 https://evolution-bio.com/?p=15887 More Efficient and Affordable Large-Scale Biomanufacturing: Have Novo Nordisk Foundation Made a Major Breakthrough? https://evolution-bio.com/news-analysis/more-efficient-and-affordable-large-scale-biomanufacturing-have-novo-nordisk-made-a-major-breakthrough/ Thu, 22 Feb 2018 17:16:14 +0000 https://evolution-bio.com/?p=15880 Global Drug Development IPO Review: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017 https://evolution-bio.com/news-analysis/global-drug-development-ipo-review-6-4b-raised-as-bullish-investors-back-biologics-gene-therapies-despite-slowed-growth-in-2017/ Wed, 31 Jan 2018 16:19:08 +0000 https://evolution-bio.com/?p=15869 Manufacturing Gene Therapies: An Impending Crisis or Temporary Growing Pains? https://evolution-bio.com/news-analysis/manufacturing-gene-therapies-an-impending-crisis-or-temporary-growing-pain/ Wed, 24 Jan 2018 15:20:20 +0000 https://evolution-bio.com/?p=15866 Evaluating the Monogenic Gene Therapy Pipeline: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis? https://evolution-bio.com/news-analysis/evaluating-the-monogenic-gene-therapy-pipeline-will-spark-therapeutics-luxturna-avoid-the-fate-of-glybera-strimvelis/ Tue, 24 Oct 2017 15:13:37 +0000 https://evolution-bio.com/?p=15835 Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence-Driven Drug Discovery https://evolution-bio.com/news-analysis/evotec-invests-15m-euros-in-exscientia-in-latest-partnership-between-big-pharma-artificial-intelligence-driven-drug-discovery/ Tue, 17 Oct 2017 11:51:06 +0000 https://evolution-bio.com/?p=15827 2017 Global Therapeutic IPO Market: 121% YOY Increase in Funds Raised Despite Bearish Q3 https://evolution-bio.com/news-analysis/2017-global-therapeutic-ipo-market-121-yoy-increase-in-funds-raised-despite-bearish-q3/ Thu, 05 Oct 2017 14:59:55 +0000 https://evolution-bio.com/?p=15819